Grufity logoGrufity logo

AMGN

284.68USD+1.39(+0.49%)Delayedas of 07 Dec 2022, 03:04 pm

Amgen Inc

Market Summary

USD284.68+1.39Delayedas of 07 Dec 2022, 03:04 pm
0.49%

AMGN Alerts

AMGN Stock Price

RSI Chart

Valuation

Market Cap

146.5B

Price/Earnings

22.27

Price/Sales

5.55

Price/Cashflow

15.72

MarketCap/EBT

19.55

Price/Sales

Profitability

EBT Margin

28.40%

Return on Equity

271.85%

Return on Assets

11.09%

Fundamentals

Revenue

Revenue (TTM)

26.3B

Revenue Y/Y

-0.81%

Revenue Q/Q

0.88%

Earnings

Earnings (TTM)

6.8B

Earnings Y/Y

13.75%

Earnings Q/Q

62.72%

Price Action

52 Week Range

202.60294.64
(Low)(High)

Last 7 days

0.5%

Last 30 days

6.0%

Last 90 days

16.5%

Trailing 12 Months

40.0%

Financial Health

Current Ratio

1.53

Debt/Equity

13.77

Debt/Cashflow

0.28

Investor Care

Dividend Yield

2.85%

Dividend/Share (TTM)

7.76

Buy Backs (1Y)

5.58%

Peers (Alternatives to Amgen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.02% 39.97%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
9.48% 32.58%
24.02
3.61
-1.26% -54.91%
59.1B
21.4B
9.55% -34.59%
4.2
2.57
80.80% 66.61%
41.3B
10.4B
3.42% 30.06%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
-1.32% 48.98%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
7.56% -29.21%
-12.87
32.5
-41.50% -607.58%
3.4B
-
0.89% -37.36%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-3.53% -59.99%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
30.71% -27.36%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
-
-13.51% -88.17%
-1.22
1.39
9.22% -22.97%
1.6B
69.7M
-4.98% -76.24%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
1.89% -30.47%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-5.25% -58.22%
-4.02
6.06
-17.11% -27.41%
458.1M
10.2M
-10.11% -90.36%
-13.56
44.06
522.71% -141.72%
218.9M
-
-26.53% -81.28%
-2.36
609.63
-71.03% -64.56%

Financials for Amgen

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.2%26,33026,38426,31625,97925,767
Earnings Before Taxes3.2%7,7297,4926,5196,7016,447
Net Income3.9%6,8356,5765,7235,8935,609
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets7.4%63,70059,29459,19661,16564,993
  Current Assets24.5%24,06219,32218,52019,38524,380
    Cash Equivalents82.6%9,5025,2036,5287,98911,969
  Inventory4.5%4,7574,5544,4114,0864,152
  Goodwill-0.1%14,84514,86514,89714,89014,665
  Current Liabilities13.6%14,33112,61812,88612,18414,842
  Long Term Debt-33,309----
    LT Debt, Current88.9%1,543817844874,288
    LT Debt, Non Current4.1%37,16135,70536,01033,22233,291
Shareholder's Equity51.0%3,6532,4199166,7008,217
  Retained Earnings0.7%-28,066.00-28,252.00-29,568.00-24,600.00-22,964.00
Shares Outstanding-0.3%534535534558565
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations6.0%9,8809,3209,3219,2618,606
Cashflow From Investing-13.8%-2,801.00-2,461.00941733-421.00
Cashflow From Financing-15.2%-9,546.00-8,286.00-9,846.00-8,271.00-5,303.00
  Dividend Payments0.9%4,1464,1074,0774,0133,955
  Buy Backs-12.0%7,8038,87210,4644,9754,737

Risks

What is the probability of a big loss on AMGN?

16.5%


Probability that Amgen stock will be more than 20% underwater in next one year

0%


Probability that Amgen stock will be more than 30% underwater in next one year.

0%


Probability that Amgen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AMGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Amgen was unfortunately bought at previous high price.

Returns

Cumulative Returns on AMGN

15.4%


10-Year Cumulative Returns

11.9%


7-Year Cumulative Returns

13.7%


5-Year Cumulative Returns

10.1%


3-Year Cumulative Returns

What are the long-term rolling returns for AMGN?

FIve years rolling returns for Amgen.

Which funds bought or sold AMGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
London & Capital Asset Management Ltd
REDUCED
-0.04
-3,002,000
37,577,000
3.51%
2022-11-23
Invst, LLC
REDUCED
-0.8
-20,000
202,000
0.04%
2022-11-23
Toroso Investments, LLC
REDUCED
-18
-1,747,000
5,521,000
0.23%
2022-11-23
Aurora Investment Counsel
SOLD OFF
-100
-1,771,000
-
-%
2022-11-23
Gould Capital, LLC
REDUCED
-0.2
-84,000
1,038,000
0.90%
2022-11-23
Eagle Bay Advisors LLC
ADDED
0.04
-43,191
547,000
0.34%
2022-11-23
FSB PREMIER WEALTH MANAGEMENT, INC.
REDUCED
-3.24
-58,000
497,000
0.29%
2022-11-22
IHT Wealth Management, LLC
ADDED
46.59
522,000
1,979,000
0.15%
2022-11-22
SMITH CHAS P & ASSOCIATES PA CPAS
ADDED
8.67
3,000
424,000
0.04%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
39.87
2,169,000
9,502,000
0.29%

1–10 of 45

Latest Funds Activity

Are funds buying AMGN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own AMGN

Amgen News

Best Stocks

Comments from Jefferies Financial Group Regarding Amgen Inc.'s FY2022 Earnings.57 minutes ago

AMGN Fair Value

Recent SEC filings of Amgen

View All Filings
Date Filed Form Type Document
Nov 10, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 04, 2022
10-Q
Quarterly Report
Nov 03, 2022
4
Insider Trading

Latest Insider Trading transactions for AMGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-09
Khosla Rachna
SOLD
-113,352
292.9
-387
SVP, Business Development
2022-11-08
Grygiel Nancy A.
SOLD
-159,977
293.535
-545
SVP & CCO
2022-11-08
ISHRAK OMAR
ACQUIRED
-
-
222.306
-
2022-11-08
Drake Michael V
ACQUIRED
-
-
171.005
-
2022-11-08
Kullman Ellen Jamison
ACQUIRED
-
-
222.306
-
2022-11-05
Khosla Rachna
SOLD FOR TAXES
-45,198.7
269.04
-168
SVP, Business Development
2022-11-05
Louie Linda H.
SOLD FOR TAXES
-12,106.8
269.04
-45
VP, Finance & CAO
2022-11-05
Grygiel Nancy A.
SOLD FOR TAXES
-64,569.6
269.04
-240
SVP & CCO
2022-11-05
Miller Derek
SOLD FOR TAXES
-16,949.5
269.04
-63
SVP, Human Resources
2022-11-02
Louie Linda H.
SOLD FOR TAXES
-34,007.5
272.06
-125
VP, Finance & CAO

1–10 of 50

Robert A. Bradway
24200
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AMGN Income Statement

2022-09-30
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 6,652$ 6,706$ 19,484$ 19,133
Operating expenses:    
Cost of sales1,5881,6094,6594,736
Research and development1,1121,4223,1103,471
Acquired in-process research and development0001,505
Selling, general and administrative1,2871,3053,8423,943
Other5(8)537143
Total operating expenses3,9924,32812,14813,798
Operating income2,6602,3787,3365,335
Interest expense, net(368)(296)(991)(862)
Other income (expense), net10073(747)97
Income before income taxes2,3922,1555,5984,570
Provision for income taxes249271662576
Net income$ 2,143$ 1,884$ 4,936$ 3,994
Earnings per share:    
Basic (in usd per share)$ 4.01$ 3.32$ 9.16$ 6.98
Diluted (in usd per share)$ 3.98$ 3.31$ 9.11$ 6.93
Shares used in calculation of earnings per share:    
Basic (in shares)535567539572
Diluted (in shares)538570542576
Product sales    
Revenues:    
Total revenues$ 6,237$ 6,320$ 18,249$ 18,026
Other revenues    
Revenues:    
Total revenues$ 415$ 386$ 1,235$ 1,107

AMGN Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 9,502$ 7,989
Marketable securities1,97648
Trade receivables, net5,3264,895
Inventories4,7574,086
Other current assets2,5012,367
Total current assets24,06219,385
Property, plant and equipment, net5,1885,184
Intangible assets, net13,26615,182
Goodwill14,84514,890
Other noncurrent assets6,3396,524
Total assets63,70061,165
Current liabilities:  
Accounts payable1,2041,366
Accrued liabilities11,58410,731
Current portion of long-term debt1,54387
Total current liabilities14,33112,184
Long-term debt37,16133,222
Long-term tax liabilities5,6806,594
Other noncurrent liabilities2,8752,465
Contingencies and commitments
Stockholders’ equity:  
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—533.5 shares in 2022 and 558.3 shares in 202132,37132,096
Accumulated deficit(28,066)(24,600)
Accumulated other comprehensive loss(652)(796)
Total stockholders’ equity3,6536,700
Total liabilities and stockholders’ equity$ 63,700$ 61,165